Natixis Acquires New Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Natixis acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 92,250 shares of the company's stock, valued at approximately $1,738,000. Natixis owned 0.20% of Pacira BioSciences at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Sterling Capital Management LLC raised its stake in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after acquiring an additional 1,208 shares during the period. Caitlin John LLC raised its position in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after buying an additional 513 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after buying an additional 918 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on PCRX. Barclays increased their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. HC Wainwright increased their target price on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their price target for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, Pacira BioSciences currently has an average rating of "Hold" and an average target price of $26.67.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX traded up $0.61 during trading on Monday, reaching $26.33. 266,751 shares of the company traded hands, compared to its average volume of 978,058. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The firm has a market capitalization of $1.22 billion, a PE ratio of -12.91 and a beta of 0.71. The company's 50 day moving average is $24.50 and its two-hundred day moving average is $21.53.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.